<DOC>
	<DOCNO>NCT01495468</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , parallel control phase III study , compare pegylated somatropin Jintropin AQ ( somatropin liquid injection , daily administration formulation ) . All subject randomize two group , test group ( PEG somatorpin ) control group ( Jintropin AQ ) , 200 child enrol test group 100 child enrol control group . Considering case loss clinical study , 20 % patient add group , 240 child test group 120 child control group , totally 360 child enrol phase III clinical study . Whole treatment last 6 month , 4 time follow-up carry point baseline , 1 month , 3 month 6 month treatment . The evaluation primary time point 3 month 6 month treatment , treatment le 6 month , evaluation would make treatment finish .</brief_summary>
	<brief_title>Phase III Clinical Study Pegylated Somatropin ( PEG Somatropin ) Treat Growth Hormone Deficiency Children</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Subjects height less two standard deviation ( SD ) median height individual age height , growth velocity ( CV≤4.0 cm/yr ) , GH peak concentration &lt; 7.0ng/ml two difference provocative test , Bone age ( BA ) ≤9 year girls ≤10 year boys , least 2 year less his/her chronological age ( CA ) preadolescence ( Tanner stage 1 ) CA &gt; 3 year height value record 3 month start GH treatment calculate pretreatment GV . receive prior GH treatment . sign inform consent 1. patient positive hepatitis B eantibody ( HBeAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis B e antigen ( HBeAg ) 2.Known hypersensitivity Somatropin component study product . 3. severe cardiopulmonary hematological disease , current past history malignant tumor , immunodeficiency disease , mental disease 4. growth disorder , Turner syndrome , constitutional delay growth puberty , Laron syndrome 5 . Subjects take part clinical trial study 3 month . 6 . Other condition opinion investigator preclude enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pegylated somatropin</keyword>
	<keyword>PEG-rhGH</keyword>
	<keyword>growth hormone</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>phase III study</keyword>
</DOC>